UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 103

Sortiert nach

What Exactly Is Inflammation (and What Is It Not?)

International journal of molecular sciences, 2022-11, Vol.23 (23), p.14905

2022

Volltextzugriff (PDF)

Follow the ATP: tumor energy production: a perspective

Anti-cancer agents in medicinal chemistry, 2014-01, Vol.14 (9), p.1187

2014

Volltextzugriff (PDF)

Nucleocapsid as a next-generation COVID-19 vaccine candidate

International journal of infectious diseases, 2022-09, Vol.122, p.529-530

2022

Volltextzugriff (PDF)

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)

Frontiers in immunology, 2023-03, Vol.14, p.1104753-1104753

2023

Volltextzugriff (PDF)

RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist

Frontiers in oncology, 2023-05, Vol.13, p.1204143-1204143

2023

Volltextzugriff (PDF)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma

Frontiers in oncology, 2023-06, Vol.13, p.1176448-1176448

2023

Volltextzugriff (PDF)

Could nucleocapsid be a next-generation COVID-19 vaccine candidate – author's reply

International journal of infectious diseases, 2022-12, Vol.125, p.227-227

2022

Volltextzugriff (PDF)

Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot

Cancers, 2022-09, Vol.14 (19), p.4701

2022

Volltextzugriff (PDF)

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis

Translational oncology, 2018-06, Vol.11 (3), p.771-778

2018

Volltextzugriff (PDF)

Patent and Marketing Exclusivities 101 for Drug Developers

Recent patents on biotechnology, 2023, Vol.17 (3), p.257

2023

Volltextzugriff (PDF)

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance

Neoplasia (New York, N.Y.), 2015-09, Vol.17 (9), p.716-722

2015

Volltextzugriff (PDF)

Hypothesis: AdAPT-001 and pseudoprogression – when seeing is not necessarily believing

Journal for immunotherapy of cancer, 2024-06, Vol.12 (6), p.e008809

2024

Volltextzugriff (PDF)

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

Oncoimmunology, 2020-01, Vol.9 (1), p.1746172-1746172

2020

Volltextzugriff (PDF)

Data Management 101 for Drug Developers: A Peek Behind the Curtain

Clinical and translational science, 2023-09, Vol.16 (9), p.1497-1509

2023

Volltextzugriff (PDF)

Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient

Case reports in oncology, 2023-01, Vol.16 (1), p.178-182

2023

Volltextzugriff (PDF)

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet

JIM - high impact case reports, 2018-01, Vol.6, p.2324709618760080-2324709618760080

2018

Volltextzugriff (PDF)

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)

Oncoimmunology, 2018-09, Vol.7 (9), p.e1478648-e1478648

2018

Volltextzugriff (PDF)

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

Case reports in oncology, 2016-01, Vol.9 (1), p.62-67

2016

Volltextzugriff (PDF)

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

Case reports in oncology, 2016-01, Vol.9 (1), p.45-50

2016

Volltextzugriff (PDF)

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Case reports in oncology, 2015-10, Vol.8 (3), p.461-465

2015

Volltextzugriff (PDF)

Dysphonia after Bevacizumab Rechallenge: A Case Report

Case reports in oncology, 2015-10, Vol.8 (3), p.423-425

2015

Volltextzugriff (PDF)

Abstract 10336: Phase 3 Anticancer Agent, RRx-001, Ameliorates Hypoxia-Induced Pulmonary Hypertension

Circulation (New York, N.Y.), 2022-11, Vol.146 (Suppl_1)

2022

Volltextzugriff (PDF)

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

Case reports in oncology, 2016-03, Vol.9 (1), p.171-176

2016

Volltextzugriff (PDF)

Phase 3 Anticancer Agent, RRx-001, Ameliorates Hypoxia-Induced Pulmonary Hypertension

Physiology (Bethesda, Md.), 2023-05, Vol.38 (S1)

2023

Volltextzugriff (PDF)

Cardioprotection from Acute Myocardial Infarction with RRx-001, an NLRP3 Inflammasome Inhibitor, in Phase 3 for the Treatment of Cancer

Physiology (Bethesda, Md.), 2023-05, Vol.38 (S1)

2023

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(92)

Publikationsform

Sprache

Englisch
(102)
Japanisch
(2)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(53)
Life Sciences & Biomedicine
(52)
Oncology
(39)
Rrx-001
(24)
Humans
(18)
Immunotherapy
(11)
Clinical Trials
(9)
Pharmacology & Pharmacy
(9)
Cancer
(8)
Case Report
(8)
Case Reports
(8)
Chemotherapy
(7)
Review
(7)
Tumors
(7)
Lung Cancer
(6)
Patients
(6)
Animals
(5)
Covid-19
(5)
Small Molecule
(5)
Azetidines - Administration & Dosage
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

What Exactly Is Inflammation (and What Is It Not?)

Follow the ATP: tumor energy production: a perspective

Nucleocapsid as a next-generation COVID-19 vaccine candidate

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)

RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma

Could nucleocapsid be a next-generation COVID-19 vaccine candidate – author's reply

Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis

Patent and Marketing Exclusivities 101 for Drug Developers

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance

Hypothesis: AdAPT-001 and pseudoprogression – when seeing is not necessarily believing

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

Data Management 101 for Drug Developers: A Peek Behind the Curtain

Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Dysphonia after Bevacizumab Rechallenge: A Case Report

Abstract 10336: Phase 3 Anticancer Agent, RRx-001, Ameliorates Hypoxia-Induced Pulmonary Hypertension

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

Phase 3 Anticancer Agent, RRx-001, Ameliorates Hypoxia-Induced Pulmonary Hypertension

Cardioprotection from Acute Myocardial Infarction with RRx-001, an NLRP3 Inflammasome Inhibitor, in Phase 3 for the Treatment of Cancer

Suchergebnisse filtern